JP2009510134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510134A5 JP2009510134A5 JP2008533837A JP2008533837A JP2009510134A5 JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5 JP 2008533837 A JP2008533837 A JP 2008533837A JP 2008533837 A JP2008533837 A JP 2008533837A JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5
- Authority
- JP
- Japan
- Prior art keywords
- gastrin
- pharmaceutical composition
- seq
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102400000921 Gastrin Human genes 0.000 claims 12
- 108010052343 Gastrins Proteins 0.000 claims 10
- -1 gastrin compound Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 101800000285 Big gastrin Proteins 0.000 claims 4
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 102400000948 Big gastrin Human genes 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 108010066264 gastrin 17 Proteins 0.000 claims 2
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 claims 2
- FMIHGWZLPSIAFY-WGFKALLTSA-N gastrin-34 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C1=CC=C(O)C=C1 FMIHGWZLPSIAFY-WGFKALLTSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 102400000949 Gastrin-52 Human genes 0.000 claims 1
- 101800004422 Gastrin-52 Proteins 0.000 claims 1
- 102400000922 Gastrin-6 Human genes 0.000 claims 1
- 101800002467 Gastrin-6 Proteins 0.000 claims 1
- 102400000947 Gastrin-71 Human genes 0.000 claims 1
- 101800001254 Gastrin-71 Proteins 0.000 claims 1
- 101001002317 Homo sapiens Gastrin Proteins 0.000 claims 1
- 108010079943 Pentagastrin Proteins 0.000 claims 1
- 108010012944 Tetragastrin Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 claims 1
- 229960000444 pentagastrin Drugs 0.000 claims 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 1
- 229960004937 saxagliptin Drugs 0.000 claims 1
- 108010033693 saxagliptin Proteins 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960001254 vildagliptin Drugs 0.000 claims 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 1
Claims (8)
- 治療有効量のＤＰＰ−ＩＶ阻害剤及びガストリン化合物と、薬学的に許容される担体、賦形剤又はビヒクルとを含む、糖尿病治療のための薬学的組成物。
- 薬学的に許容される賦形剤、担体又はビヒクルに相乗的に有効な量の前記ＤＰＰ−ＩＶ阻害剤及び前記ガストリン化合物を含む、請求項１に記載の薬学的組成物。
- 前記ガストリン化合物が、ガストリン７１［配列番号５］、ガストリン５２［配列番号６］、ガストリン３４（大ガストリン）［配列番号１又は２］、ガストリン１７（小ガストリン）［配列番号３又は１４］、ガストリン１４［配列番号７］、ガストリン８、ガストリン６［配列番号８又は９］、ペンタガストリン、又はテトラガストリンである、上記請求項１または２に記載の薬学的組成物。
- 前記ガストリン化合物がガストリン１７又はその類似体及び誘導体である、請求項１〜３の何れかに記載の薬学的組成物。
- 前記ガストリン化合物が、アミノ酸位１５［配列番号４］にＬｅｕ残基を有する１７個のアミノ酸残基を有する合成ヒトガストリンＩである、請求項１〜４の何れかに記載の薬学的組成物。
- 前記ガストリン化合物がガストリン３４又はその類似体及び誘導体である、請求項１〜５の何れかに記載の薬学的組成物。
- 前記ＤＰＰ−ＩＶ阻害剤が、シタグリプチン、ビルダグリプチン、ＰＳＮ９３０１、サクサグリプチン、Ｎ−（Ｎ’−置換グリシル）−２−シアノピロリジン、Ｌ−ｔｈｒｅｏ−イソロイシルチアゾリジン（Ｐ３２／９８）、Ｌ−ａｌｌｏ−イソロイシルチアゾリジン、Ｌ−ｔｈｒｅｏ−イソロイシルピロリジンおよびＬ−ａｌｌｏ−イソロイシルピロリジンよりなる群から選択される、請求項１〜６の何れかに記載の薬学的組成物。
- 糖尿病がII型糖尿病である、請求項１〜７の何れかに記載の薬学的組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72491905P | 2005-10-07 | 2005-10-07 | |
| PCT/CA2006/001644 WO2007041833A1 (en) | 2005-10-07 | 2006-10-06 | Combined use of dpp iv inhibitors and gastrin compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009510134A JP2009510134A (ja) | 2009-03-12 |
| JP2009510134A5 true JP2009510134A5 (ja) | 2009-09-24 |
Family
ID=37942251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008533837A Withdrawn JP2009510134A (ja) | 2005-10-07 | 2006-10-06 | Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20090054314A1 (ja) |
| EP (1) | EP1951286A4 (ja) |
| JP (1) | JP2009510134A (ja) |
| CN (1) | CN101365476A (ja) |
| AU (1) | AU2006301892A1 (ja) |
| BR (1) | BRPI0616949A2 (ja) |
| CA (1) | CA2625150A1 (ja) |
| WO (1) | WO2007041833A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6992060B2 (en) | 2001-01-12 | 2006-01-31 | Waratah Pharmaceuticals, Inc. | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes |
| IL165285A0 (en) | 2002-06-07 | 2005-12-18 | Waratah Pharmaceuticals Inc | Compositions and methods for treating diabetes |
| EP1837031B1 (en) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| WO2008098256A1 (en) * | 2007-02-09 | 2008-08-14 | Bristol-Myers Squibb Company | Methods for identifying patients with an increased likelihood of responding to dpp-iv inhibitors |
| WO2009033681A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Cyclo-argd as a therapeutic agent |
| WO2009033767A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US8404727B2 (en) * | 2009-01-07 | 2013-03-26 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor |
| US8808689B1 (en) * | 2012-09-27 | 2014-08-19 | Perle Bioscience, Inc. | Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent |
| AU2018351059B2 (en) | 2017-10-19 | 2022-05-12 | Teijin Pharma Limited | Benzimidazole derivatives and their uses |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| US5885956A (en) * | 1992-12-14 | 1999-03-23 | Research Triangle Pharmaceuticals | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US20040037818A1 (en) * | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| CA2673615C (en) * | 2000-01-21 | 2013-07-16 | Novartis Ag | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| PT2266665T (pt) * | 2000-03-31 | 2016-07-07 | Royalty Pharma Collection Trust | Método para o melhoramento da sinalização de ilhéus na diabetes mellitus e para a sua prevenção |
| US6992060B2 (en) * | 2001-01-12 | 2006-01-31 | Waratah Pharmaceuticals, Inc. | Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes |
| JP2004526449A (ja) * | 2001-03-29 | 2004-09-02 | イクシオン・バイオテクノロジー・インコーポレーテッド | 非膵性幹細胞の膵分化経路への分化転換法 |
| US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| WO2003100024A2 (en) * | 2002-05-24 | 2003-12-04 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| IL165285A0 (en) * | 2002-06-07 | 2005-12-18 | Waratah Pharmaceuticals Inc | Compositions and methods for treating diabetes |
| EP1837031B1 (en) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| JP2006506386A (ja) * | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ， インコーポレイテッド | 糖尿病の処置 |
| US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| RU2006131046A (ru) * | 2004-01-30 | 2008-03-10 | Уэрейта Фармасьютикалз, Инк. (Ca) | Совместное применение агониста glp-1 и соединений гастрина |
-
2006
- 2006-10-06 BR BRPI0616949-0A patent/BRPI0616949A2/pt not_active IP Right Cessation
- 2006-10-06 US US11/545,025 patent/US20090054314A1/en not_active Abandoned
- 2006-10-06 CN CNA2006800458916A patent/CN101365476A/zh active Pending
- 2006-10-06 CA CA002625150A patent/CA2625150A1/en not_active Abandoned
- 2006-10-06 US US12/083,175 patent/US20100144613A1/en not_active Abandoned
- 2006-10-06 WO PCT/CA2006/001644 patent/WO2007041833A1/en active Application Filing
- 2006-10-06 AU AU2006301892A patent/AU2006301892A1/en not_active Abandoned
- 2006-10-06 JP JP2008533837A patent/JP2009510134A/ja not_active Withdrawn
- 2006-10-06 EP EP06790802A patent/EP1951286A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009510134A5 (ja) | ||
| JP2013155195A5 (ja) | ||
| JP2005516885A5 (ja) | ||
| JP2009538348A5 (ja) | ||
| WO2008131149A3 (en) | Crystal forms of saxagliptin and processes for preparing same | |
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
| NZ592705A (en) | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication | |
| WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors | |
| TW200400199A (en) | Hepatitis C inhibitor tri-peptides | |
| WO2008021733A3 (en) | Tetrazolyl acyclic hepatitis c serine protease inhibitors | |
| EP1673385A1 (en) | Macrocyclic peptides active against the hepatitis c virus | |
| WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
| WO2007143694A3 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
| WO2011080102A3 (en) | Glp-1 analogues and derivatives | |
| WO2009053828A3 (en) | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors | |
| JP2013503862A5 (ja) | ||
| JP2010505831A5 (ja) | ||
| WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
| WO2007096662A3 (en) | Cancer imaging and treatment | |
| WO2008069917A3 (en) | Novel cyclic peptides | |
| JP2010536714A5 (ja) | ||
| MX2010008108A (es) | Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo. |